Simple Summary Integrins, a superfamily of cell adhesion receptors, were extensively
investigated as therapeutic targets over the last decades, motivated by their multiple …

Simple Summary Somatostatin receptors (SSTs) are of particular interest in oncology
because these proteins are overexpressed on the cell membranes of different human …

Identified in 1973, somatostatin (SST) is a cyclic hormone peptide with a short biological half-
life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five …

Simple Summary Prostate cancer remains one of the leading causes of cancer death in men
worldwide. Despite the recent success in the development and clinical application of …

Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a
very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding …

In this article, we provide an overview of established and emerging conventional nuclear
medicine and PET imaging biomarkers, as the diagnostic nuclear medicine portfolio is …

Despite numerous clinical trials and pre-clinical developments, the treatment of glioblastoma
(GB) remains a challenge. The current survival rate of GB averages one year, even with an …

Theranostic nuclear oncology is on the cusp of adoption into routine clinical management of
neuroendocrine tumours (NETs) following publication of the Phase 3 randomised controlled …

Peptide receptor radionuclide therapy (PRRT) is an established treatment for nonoperable
or metastatic neuroendocrine neoplasms that highly and frequently express somatostatin …

The term theranostics is today perceived as the combination of a predictive biomarker with a
therapeutic agent. Use of this term began at the end of the last century and has steadily …